Depatux-M
AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
May 20, 2019Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
